For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...

Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ ...

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

Study suggests a path forward for device therapy, though caveats are plenty ...

The woman who had no concerning medical history was in for a shock when doctors found a tumor inside her heart.

Researchers have discovered in a new research that among patients with atrial fibrillation at high risk for both stroke and ...

Atrial fibrillation (AFib) is an irregular and often very rapid heart rhythm, also called an arrhythmia and can create blood ...

Patients who have had an embolic stroke of undetermined source (ESUS) and have moderate-to-severe left atrial enlargement may benefit from empiric treatment with a direct oral anticoagulant (DOAC), a ...